JP2017535285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535285A5 JP2017535285A5 JP2017543332A JP2017543332A JP2017535285A5 JP 2017535285 A5 JP2017535285 A5 JP 2017535285A5 JP 2017543332 A JP2017543332 A JP 2017543332A JP 2017543332 A JP2017543332 A JP 2017543332A JP 2017535285 A5 JP2017535285 A5 JP 2017535285A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 96
- 239000000427 antigen Substances 0.000 claims description 93
- 102000036639 antigens Human genes 0.000 claims description 93
- 108091007433 antigens Proteins 0.000 claims description 93
- 102000004889 Interleukin-6 Human genes 0.000 claims description 26
- 108090001005 Interleukin-6 Proteins 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 17
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 15
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 15
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 14
- 201000011190 diabetic macular edema Diseases 0.000 claims description 14
- 230000009885 systemic effect Effects 0.000 claims description 12
- 206010013774 Dry eye Diseases 0.000 claims description 10
- 238000009825 accumulation Methods 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 10
- 102000001708 Protein Isoforms Human genes 0.000 claims description 9
- 108010029485 Protein Isoforms Proteins 0.000 claims description 9
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 5
- 206010038848 Retinal detachment Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 102000052611 human IL6 Human genes 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 108010081667 aflibercept Proteins 0.000 claims description 4
- 229940051306 eylea Drugs 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 229960003989 tocilizumab Drugs 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 208000022873 Ocular disease Diseases 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 238000001516 cell proliferation assay Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 208000019793 rhegmatogenous retinal detachment Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077105P | 2014-11-07 | 2014-11-07 | |
| US62/077,105 | 2014-11-07 | ||
| US201462087448P | 2014-12-04 | 2014-12-04 | |
| US62/087,448 | 2014-12-04 | ||
| US201562247705P | 2015-10-28 | 2015-10-28 | |
| US62/247,705 | 2015-10-28 | ||
| PCT/US2015/059532 WO2016073890A1 (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535285A JP2017535285A (ja) | 2017-11-30 |
| JP2017535285A5 true JP2017535285A5 (OSRAM) | 2018-12-13 |
| JP6594438B2 JP6594438B2 (ja) | 2019-10-23 |
Family
ID=54602042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543332A Active JP6594438B2 (ja) | 2014-11-07 | 2015-11-06 | 改善されたｉｌ−６抗体 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US11142571B2 (OSRAM) |
| EP (3) | EP4268843B1 (OSRAM) |
| JP (1) | JP6594438B2 (OSRAM) |
| KR (2) | KR102636726B1 (OSRAM) |
| CN (1) | CN107249631B (OSRAM) |
| AU (1) | AU2015342882B2 (OSRAM) |
| CA (1) | CA2965689C (OSRAM) |
| CL (1) | CL2017001135A1 (OSRAM) |
| CO (1) | CO2017005404A2 (OSRAM) |
| CR (1) | CR20170231A (OSRAM) |
| DK (2) | DK4268843T3 (OSRAM) |
| EA (1) | EA035199B1 (OSRAM) |
| ES (1) | ES2756275T3 (OSRAM) |
| FI (1) | FI4268843T3 (OSRAM) |
| HR (2) | HRP20251312T1 (OSRAM) |
| HU (1) | HUE046181T2 (OSRAM) |
| IL (1) | IL251858B (OSRAM) |
| LT (1) | LT4268843T (OSRAM) |
| MA (1) | MA51554A (OSRAM) |
| MX (2) | MX385206B (OSRAM) |
| MY (1) | MY185114A (OSRAM) |
| PE (1) | PE20171107A1 (OSRAM) |
| PH (1) | PH12017500809B1 (OSRAM) |
| PL (1) | PL3215530T3 (OSRAM) |
| PT (2) | PT4268843T (OSRAM) |
| RS (2) | RS59805B1 (OSRAM) |
| SA (1) | SA517381458B1 (OSRAM) |
| SG (2) | SG10202103420PA (OSRAM) |
| SI (1) | SI3215530T1 (OSRAM) |
| UA (1) | UA122673C2 (OSRAM) |
| WO (1) | WO2016073890A1 (OSRAM) |
| ZA (1) | ZA201702985B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102725051B1 (ko) | 2015-09-23 | 2024-11-04 | 제넨테크, 인크. | 항-vegf 항체의 최적화된 변이체들 |
| US20190046642A1 (en) * | 2016-02-23 | 2019-02-14 | Eleven Biotherapeutics, Inc. | Il-6 antagonist formulations and uses thereof |
| WO2018115003A2 (en) * | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| AR111249A1 (es) | 2017-03-22 | 2019-06-19 | Genentech Inc | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares |
| CA3055985A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
| CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
| TW202144410A (zh) | 2020-03-13 | 2021-12-01 | 美商建南德克公司 | 抗介白素－３３抗體及其用途 |
| CN120757643A (zh) | 2020-03-24 | 2025-10-10 | 基因泰克公司 | Tie2结合剂及其使用方法 |
| AU2021361108A1 (en) | 2020-10-15 | 2023-05-25 | F. Hoffmann-La Roche Ag | Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery |
| CN116355825A (zh) * | 2022-02-25 | 2023-06-30 | 南京工业大学 | 一种强化纤维素合成来提高人表皮生长因子分泌生产效率的方法 |
| CN115343483B (zh) * | 2022-08-12 | 2024-11-26 | 苏州邦器生物技术有限公司 | 一种自身免疫性糖尿病检测用试剂盒及其制备方法 |
| KR20250093319A (ko) * | 2022-10-24 | 2025-06-24 | 에프. 호프만-라 로슈 아게 | Il-6 길항제에 대한 반응 예측 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
| TW311927B (OSRAM) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
| EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
| US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
| PT1137941E (pt) | 1998-12-10 | 2009-10-15 | Brystol Myers Squibb Company | Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| PT1390535E (pt) | 2001-04-26 | 2010-10-04 | Amgen Mountain View Inc | Bibliotecas combinatórias de domínios monoméricos |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| MXPA04011004A (es) | 2002-05-07 | 2005-01-25 | Control Delivery Sys Inc | Procesos para formar un dispositivo de administracion de farmaco. |
| EP1572103A4 (en) | 2002-11-15 | 2008-02-13 | Centocor Inc | ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS |
| AU2004308482A1 (en) | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1966244B1 (en) | 2005-12-30 | 2012-03-21 | Merck Patent GmbH | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| WO2007104529A2 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| MX2008014692A (es) | 2006-05-19 | 2009-08-18 | Alder Biopharmaceuticals Inc | Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno. |
| ES2721753T3 (es) * | 2007-05-21 | 2019-08-05 | Alderbio Holdings Llc | Anticuerpos contra IL-6 y usos de los mismos |
| WO2009035707A1 (en) | 2007-09-14 | 2009-03-19 | Acambis Inc. | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| US8043620B2 (en) | 2007-11-21 | 2011-10-25 | Amgen Inc. | Wise binding agents and epitopes |
| US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
| NZ621174A (en) | 2008-01-15 | 2015-09-25 | Abbvie Deutschland | Powdered protein compositions and methods of making same |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| ES2395231T3 (es) | 2008-09-12 | 2013-02-11 | Kdf Co., Ltd. | Dispositivo de proyección de agua en forma de surtidor |
| WO2010039750A2 (en) | 2008-10-01 | 2010-04-08 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| CN102224169A (zh) | 2008-11-26 | 2011-10-19 | 葛兰素集团有限公司 | 多肽、抗体可变结构域和拮抗剂 |
| BRPI1007005A2 (pt) | 2009-01-29 | 2016-03-22 | Medimmune Llc | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| EP2593142B8 (en) | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| SG11201408538PA (en) | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| BR112015008186A2 (pt) | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
| AU2013342163B2 (en) * | 2012-11-08 | 2018-08-16 | F. Hoffmann-La Roche Ltd | IL-6 antagonists and uses thereof |
| MX2016000364A (es) | 2013-07-12 | 2016-05-09 | Ophthotech Corp | Metodos para tratar o prevenir afecciones oftalmologicas. |
| WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2015
- 2015-11-06 DK DK23189385.0T patent/DK4268843T3/da active
- 2015-11-06 SG SG10202103420PA patent/SG10202103420PA/en unknown
- 2015-11-06 PH PH1/2017/500809A patent/PH12017500809B1/en unknown
- 2015-11-06 WO PCT/US2015/059532 patent/WO2016073890A1/en not_active Ceased
- 2015-11-06 RS RS20191447A patent/RS59805B1/sr unknown
- 2015-11-06 KR KR1020177014412A patent/KR102636726B1/ko active Active
- 2015-11-06 CA CA2965689A patent/CA2965689C/en active Active
- 2015-11-06 KR KR1020247004699A patent/KR102770849B1/ko active Active
- 2015-11-06 LT LTEP23189385.0T patent/LT4268843T/lt unknown
- 2015-11-06 ES ES15797538T patent/ES2756275T3/es active Active
- 2015-11-06 AU AU2015342882A patent/AU2015342882B2/en active Active
- 2015-11-06 EA EA201791005A patent/EA035199B1/ru not_active IP Right Cessation
- 2015-11-06 HU HUE15797538A patent/HUE046181T2/hu unknown
- 2015-11-06 DK DK15797538T patent/DK3215530T3/da active
- 2015-11-06 MX MX2017005992A patent/MX385206B/es unknown
- 2015-11-06 RS RS20251073A patent/RS67353B1/sr unknown
- 2015-11-06 US US15/524,727 patent/US11142571B2/en active Active
- 2015-11-06 HR HRP20251312TT patent/HRP20251312T1/hr unknown
- 2015-11-06 EP EP23189385.0A patent/EP4268843B1/en active Active
- 2015-11-06 PT PT231893850T patent/PT4268843T/pt unknown
- 2015-11-06 IL IL251858A patent/IL251858B/en unknown
- 2015-11-06 JP JP2017543332A patent/JP6594438B2/ja active Active
- 2015-11-06 PE PE2017000804A patent/PE20171107A1/es unknown
- 2015-11-06 SI SI201530995T patent/SI3215530T1/sl unknown
- 2015-11-06 PL PL15797538T patent/PL3215530T3/pl unknown
- 2015-11-06 MY MYPI2017000609A patent/MY185114A/en unknown
- 2015-11-06 MA MA051554A patent/MA51554A/fr unknown
- 2015-11-06 EP EP19189890.7A patent/EP3632931A1/en active Pending
- 2015-11-06 FI FIEP23189385.0T patent/FI4268843T3/fi active
- 2015-11-06 UA UAA201705592A patent/UA122673C2/uk unknown
- 2015-11-06 PT PT157975384T patent/PT3215530T/pt unknown
- 2015-11-06 HR HRP20191945TT patent/HRP20191945T1/hr unknown
- 2015-11-06 CN CN201580065652.6A patent/CN107249631B/zh active Active
- 2015-11-06 EP EP15797538.4A patent/EP3215530B9/en active Active
- 2015-11-06 SG SG11201703574VA patent/SG11201703574VA/en unknown
- 2015-11-06 CR CR20170231A patent/CR20170231A/es unknown
-
2017
- 2017-04-28 ZA ZA201702985A patent/ZA201702985B/en unknown
- 2017-05-03 SA SA517381458A patent/SA517381458B1/ar unknown
- 2017-05-05 CL CL2017001135A patent/CL2017001135A1/es unknown
- 2017-05-08 MX MX2021008663A patent/MX2021008663A/es unknown
- 2017-05-30 CO CONC2017/0005404A patent/CO2017005404A2/es unknown
-
2021
- 2021-09-13 US US17/473,696 patent/US20220169719A1/en not_active Abandoned
-
2024
- 2024-05-13 US US18/662,445 patent/US20250059270A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535285A5 (OSRAM) | ||
| JP6480338B2 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| JP2016504416A5 (OSRAM) | ||
| JP7107914B2 (ja) | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 | |
| JP2010528047A5 (OSRAM) | ||
| WO2008154251A4 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
| EP2021026A1 (en) | Use of il-i antibodies for treating ophthalmic disorders | |
| JP2011504872A5 (OSRAM) | ||
| IL240898A (en) | Antibodies against a5c for the preparation of drugs for the treatment of related diseases cause an increase | |
| KR102770849B1 (ko) | 향상된 il-6 항체 | |
| TWI612059B (zh) | 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體 | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| JP2019510078A5 (OSRAM) | ||
| JP6033459B2 (ja) | Ｂｍｐ−６抗体 | |
| JP2014532072A5 (OSRAM) | ||
| US9932397B2 (en) | VEGFA/Ang2 Compounds | |
| CN104507964A (zh) | P2x7受体拮抗剂和激动剂 | |
| US20240052034A1 (en) | Multi-paratopic anti-pd-1 antibodies and uses thereof | |
| JP2020536495A (ja) | 抗ｌａｇ−３抗体及びその使用 | |
| CN103003302B (zh) | 人源化和嵌合抗-备解素抗体 | |
| IL273538B2 (en) | Anti-trkb monoclonal antibodies and methods of use | |
| JP2021507677A5 (OSRAM) | ||
| JP2011503094A5 (OSRAM) | ||
| KR20230010239A (ko) | 항-il-33 항체의 제형물 |